Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2007 / Cilt: 17 - Sayı: 3

Cholangiocarcinoma

Kolanjiokarsinom

Pages
173–183
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CCA is frequently diagnosed at an advanced stage of the disease and the prognosis is usually poor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cholangiocarcinoma (CCA) is the second most common primary hepatic malignant tumor and originates from anywhere along the intrahepatic or extrahepatic biliary tract.
📊
Key Findings & Data:Its incidence has increased during the few decades.
💡
Conclusion & Impact:CCA is frequently diagnosed at an advanced stage of the disease and the prognosis is usually poor.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Moleküler biyoloji · Neoplazmlar · glandüler ve epitelyal

Abstract

Cholangiocarcinoma (CCA) is the second most common primary hepatic malignant tumor and originates from anywhere along the intrahepatic or extrahepatic biliary tract. Its incidence has increased during the few decades. Risk factors for CCA are infection, biliary stasis or exposure to carcinogen, nevertheless, the exact cause is unknown. The clinical presentations of CCA depend on the location of the tumor. Patients with extrahepatic CCA usually present with painless jaundice, pruritus and dark urine, while patients with intrahepatic CCA complaint of abdominal pain. Surgery is the only curative treatment for patients with CCA. The success of surgical treatment depends on the location and extent of the tumor in the biliary tract. CCA is frequently diagnosed at an advanced stage of the disease and the prognosis is usually poor.

Özet

Kolanjiokarsinom (KKA) ekstrahepatik veya intrahepatik safra duktuslarının herhangi bir yerinden köken alan malign bir tümördür ve karaciğerin primer tümörleri arasında görülme sıklığı ikinci sıradadır. Bunun yanında son birkaç dekaddır insidansı artmıştır. KKA için risk faktörlerinin çoğu infeksiyon, biliyer staz ve karsinojenler ile karşılaşma ile ilişkilendirilmiştir. Bununla birlikte kesin nedeni bilinmemektedir. KKA’nın klinik prezentasyonu tümörün lokalizasyonuna bağlıdır. Ekstrahepatik KKA’sı olan hastalar genellikle ağrısız sarılık, kaşıntı ve koyu renkli idrar şikayetleri ile başvururken intrahepatik KKA’sı olan hastalar ağrıdan şikâyet ederler. Cerrahi tedavi kolanjiokarsinomu olan hastalar için tek küratif tedavi metodudur. Cerrahi tedavinin başarısı tümörün biliyer sistemdeki lokalizasyonuna ve yayılımına bağlıdır. KKA hastalığın ileri evresinde teşhis edilir. Prognoz genellikle kötüdür.

🔖

Cite This Article

ÇOBAN, Ş., BAŞAR, Ö., ERTUĞRUL, İ. (2007). Cholangiocarcinoma. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 17 - Sayı: 3, 173–183. https://ajindex.com/articles/323327

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Khan SA, Thomas HC, Davidson BR, Taylor- Robinson SD. Cholangiocarcinoma. Lancet 366: 1303-14, 2005
  2. Strasberg SM, Drebin JA. Tumors of the biliary tree cholangiocarcinoma. Textbook of gastroenterology. Yamada T, Alpers DH, Laine L et al. (eds). Lippincott Williams & Wilkins, Philadelphia, 1999; chapter 101; pp:2201-2218
  3. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosisn and treatment of cholangiocarcinoma. The Oncologist 9: 43-57, 2004
  4. Chahal P, Baron TH. Cholangiocarcinoma. Curr Treat Options Gastroenterol 8: 493-502, 2005
  5. Blendis L, Halpren Z. An increasing incidence of cholangiocarcinoma: Why? Gastroenterology 127: 1008-9, 2004
  6. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(suppl): vi1-vi9, 2002
  7. Pomfret EA, Pomposelli J, jenkins RL. Surgical approaches to diseases of the biliary system. Schiff’s Diseases of the Liver. Schiff ER, Sorrell MF, Maddrey WC (eds). Lippincott-Raven Publishers, Philadelphia, 1999; chapter 26: pp 693- 717
  8. Chalasani N, Baluyut A, Ayaaz I, Zaman A, Sood G, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 31: 7-11, 2003
  9. Groen PC. Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? Hepatology 31:247-8, 2000
  10. Miros M, Kerlin P, Walker N, Harper J, Lynch S, et al. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 32: 1369-73, 1991
  11. Ahrendt SA, Pitt HA, Nakeep A, et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. Journal of Gastrointestinal Surgery 3:357-67, 1999
  12. Lipsett PA, Pitt HA, Colombani PM, et al. Choledochal cyst disease. A changing pattern of presention. Ann Surg 220:644-52, 1994
  13. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1:Epidemiology and etiology. J Gastroenterol Hepatol 17:1049-55, 2002
  14. Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): Clinical features, diagnosis and treatment. J Gastroenterol Hepatol 14: 1144 -9, 1999
  15. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 128: 1655-67, 2005
  16. Flavell DJ, Lucas SB. Potentiation by the human liver fluke, opisthorchis viverrini, of the carcinogenic action of N-nitrosodimethylamine upon the biliary epithelium of the hamster. Br J Cancer 46